NBRST: Prospective Neo-adjuvant REGISTRY Trial

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2014 by Agendia
Sponsor:
Information provided by (Responsible Party):
Agendia
ClinicalTrials.gov Identifier:
NCT01479101
First received: November 18, 2011
Last updated: March 19, 2014
Last verified: March 2014
  Purpose

The scope of this registry study is to measure chemosensitivity as defined by pCR (primary endpoint), or endocrine sensitivity as defined by partial response (decrease in longest tumor diameter or residual cancer burden category 1 (RCB1), a primary endpoint for neo-adjuvant endocrine therapy and a secondary endpoint for neoadjuvant chemotherapy), metastasis-free survival and relapse-free survival(secondary endpoints) in molecular subgroups, determined by the established MammaPrint, BluePrint, Targetprint and Theraprint profiles in addition to possible novel expression profiles.


Condition Intervention
Breast Cancer
Other: MammaPrint 70-gene expression profile
Other: BluePrint 80 gene expression profile

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Prospective Neo-adjuvant REGISTRY Trial Linking MammaPrint, Subtyping and Treatment Response: Neoadjuvant Breast Registry - Symphony Trial (NBRST) (Pronounced "in Breast")

Resource links provided by NLM:


Further study details as provided by Agendia:

Primary Outcome Measures:
  • Chemosensitivity as defined by pCR [ Time Frame: Up to 6 months ] [ Designated as safety issue: No ]
    For neo-adjuvant chemotherapy patients the primary endpoint is pathological complete response (pCR) which is defined as the absence of invasive carcinoma in both the breast and axilla at microscopic examination of the resection specimen, regardless of the presence of carcinoma in situ. The response rate and corresponding confidence intervals will be presented as a proportion of all patients enrolled. Comparison of response rates between different molecular subgroups will be conducted using Pearson Chi-square test.

  • Endocrine sensitivity as defined by partial response (decrease in longest tumor diameter or residual cancer burden category 1 (RCB1) [ Time Frame: Up to 6 months ] [ Designated as safety issue: No ]
    The primary endpoint for patients with neo-adjuvant hormonal therapy is partial response which is defined as decrease in longest tumor diameter. The response rate and corresponding confidence intervals will be presented as a proportion of all patients enrolled. Comparison of response rates between different molecular subgroups will be conducted using Pearson Chi-square test.


Secondary Outcome Measures:
  • Correlate chemosensitivity (as defined by pCR) to TheraPrint Therapy Gene Assay results. [ Time Frame: Up to 6 months. ] [ Designated as safety issue: No ]
    Correlation of chemosensitivity and endocrine sensitivity (as defined by pCR) to TheraPrint Therapy Gene Assay results will be determined using Pearson correlation and linear fit models.

  • Assess metastasis-free survival and relapse-free survival in molecular subgroups, determined by the established MammaPrint, BluePrint, profiles. [ Time Frame: At -2-3 years and 5 years after definitive surgery. ] [ Designated as safety issue: No ]

    Kaplan-Meier curves for DMFS will be calculated for the following eight subgroups

    1. Luminal subtype
    2. ERBB2 subtype
    3. Basal subtype
    4. Luminal subtype and high risk MammaPrint
    5. Luminal subtype and low risk MammaPrint
    6. ERBB2 subtype and high risk MammaPrint
    7. ERBB2 subtype and low risk MammaPrint

  • Compare local IHC and FISH results (if available) with TargetPrint results. [ Time Frame: Baseline; before start of neo-adjuvant therapy. ] [ Designated as safety issue: No ]
    Correlation of TargetPrint ER, PR, and HER2 microarray readout with IHC/FISH assessment will be determined using Pearson correlation and linear fit models. Agreement measurements between binary microarray and IHC classifications will be based on 2-way contingency table analysis and include overall concordance, positive agreement defined as the number of samples classified positive by both IHC and TargetPrint divided by the number of positive samples using IHC, negative agreement and Cohen's Kappa coefficient score.

  • Compare the three BluePrint molecular subgroups with IHC-based subtype classification. [ Time Frame: Baseline; before start of neo-adjuvant therapy. ] [ Designated as safety issue: No ]
  • Document impact of MammaPrint, TargetPrint and BluePrint result on treatment decision. [ Time Frame: Baseline; before start neo-adjuvant therapy. ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

As part of routine breast cancer treatment, the doctor will conduct a core needle biopsy and provide tissue from the tumor to Agendia for testing. After the diagnostic test(s) from the Agendia Breast Cancer Suite have been performed on the tumor specimen, there might be some remaining tissue left.


Estimated Enrollment: 1000
Study Start Date: July 2011
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
MammaPrint, BluePrint, neo-adj CT or HT
All patients receive the MammaPrint and BluePrint gene expression profile. Treatment at the discretion of the physician while adhering to NCCN guidelines.
Other: MammaPrint 70-gene expression profile Other: BluePrint 80 gene expression profile

Detailed Description:

This will be a prospective observational, case-only study linking MammaPrint, BluePrint, TargetPrint, TheraPrint and possible additional profiles of interest to treatment response and Distant Metastases Free Survival (DMFS) and Relapse Free Survival (RFS). Only patients who receive neo-adjuvant therapy can participate.

For this project, approximately 50-70 institutions in the US will be invited to contribute clinical patient data from enrolled patients after a MammaPrint, TargetPrint, BluePrint and TheraPrint test has been successfully performed and the patient has started neo-adjuvant therapy.

Treatment is at the discretion of the physician, adhering to NCCN approved regimens or a recognized alternative.

The clinical data is to be entered online at 4 time points; amounting to four Case Report Forms (CRFs). Data will be collected on an ongoing basis, the first CRF must be completed within 6 weeks after the MammaPrint, BluePrint, TargetPrint, and TheraPrint result was provided. The second CRF should be completed 4 weeks after definitive surgery. CRF 3 and CRF4 will be completed 2-3 and 5 years after surgery.

It is expected that we will enroll around 1000 patients in 4 years.

OBJECTIVES

  • Measure chemosensitivity (as defined by pCR) or endocrine sensitivity (as defined by decrease in longest tumor diameter or RCB1)in the molecular subgroups as determined by combining MammaPrint and BluePrint results.
  • Correlate chemosensitivity (as defined by pCR) to TheraPrint Therapy Gene Assay results.
  • Compare local IHC and FISH results (if available) with TargetPrint results. Compare the three BluePrint molecular subgroups with IHC-based subtype classification.
  • Document impact of MammaPrint, TargetPrint and BluePrint result on treatment decision.
  • Assess the 2-3 and 5 years DMFS and RFS for the different molecular subgroups.
  • Measure chemosensitivity or endocrine sensitivity correlation with novel expression profiles.
  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Women with histologically proven breast cancer, who have started or are scheduled to start neo-adjuvant chemotherapy therapy or neo-adjuvant hormone therapy.

Criteria

Inclusion Criteria:

  • Women with histologically proven breast cancer, who have started or are scheduled to start neo-adjuvant chemotherapy therapy or neo-adjuvant hormone therapy, after successful MammaPrint assay
  • Age 18-90
  • Written informed consent

Exclusion Criteria:

  • Patients who have had excisional biopsy or axillary dissection Patients with confirmed distant metastatic disease
  • Tumor sample shipped to Agendia with ≤ 30% tumor cells or that fails QA or QC criteria
  • Patients who have had any prior chemotherapy, radiotherapy, or endocrine therapy for the treatment of breast cancer
  • Any serious uncontrolled intercurrent infections, or other serious uncontrolled concomitant disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01479101

Contacts
Contact: jessica gibson, BS 6193161416 jessica.gibson@agendia.com
Contact: lisette stork, MSc lisette.stork@agendia.com

  Hide Study Locations
Locations
United States, Arizona
Arizona Center for Cancer Care Recruiting
Glendale, Arizona, United States, 85306
Contact: Vicky Noboa       vnoboa@arizonaccc.com   
Principal Investigator: Clarence Sarkodee Adoo, MD         
21 Century Oncology Recruiting
Scottsdale, Arizona, United States, 85251
Contact: Dr Finkelstein, MD    480-874-8482      
Principal Investigator: Dr Finkelstein, MD         
United States, California
Fresno Breast Surgery Recruiting
Fresno, California, United States, 93710
Contact: Margaret Hadcock, MD    559-326-1222    mhadcock@fresnobreastsurgery.com   
Principal Investigator: Margaret Hadcock, MD         
Sub-Investigator: Steven Hagar, MD         
Long Beach Memorial Medical Center Recruiting
Long Beach, California, United States, 90806
Contact: Deborah Friedman    562-933-7866    DFridman@memorialcare.org   
Principal Investigator: Bichlien Nguyen, MD         
BreastLink Recruiting
Long Beach, California, United States, 90806
Contact: Kristi Maya    562-981-6101    kmaya@breastlink.com   
Principal Investigator: John Link, MD         
Community Hospital of Monterey Peninsula Recruiting
Monterey, California, United States, 93940
Contact: Mike Stuntz, MD       mikestuntz@hotmail.com   
Principal Investigator: Mike Stuntz, MD         
Alta Bates Recruiting
Oakland, California, United States, 94609
Contact: Lisa Bailey, MD       baileylisa@msn.com   
Principal Investigator: Lisa Bailey, MD         
Comprehensive Cancer Center - Palm Springs Recruiting
Palm Springs, California, United States
Contact: Laura Lee, MD       laura1.lee@tenethealth.com   
Principal Investigator: Laura Lee, MD         
Sutter Roseville Medical Center Recruiting
Roseville, California, United States, 95661
Contact: Kristen Babski    916-781-1636    BabskiK@sutterhealth.org   
Principal Investigator: Kristi Bobolis, MD         
SHARP Memorial Recruiting
San Diego, California, United States
Contact: Lisa Obregon       lisa.obregon@sharp.com   
Principal Investigator: Robert Barone, MD         
Redwood Regional Recruiting
Santa Rosa, California, United States
Contact: Kim Young       kyoung@rrmg.com   
Principal Investigator: Charles Elboim, MD         
Wellness Oncology Hematology Recruiting
West Hills, California, United States, 91307
Contact: Marylen Roldan       marylen_roldan@yahoo.com   
Contact: Limore       limorshaye@gmail.com   
Principal Investigator: Ashkan Lashkari, MD         
Wellness Oncology Hematology Recruiting
West Hills, California, United States
Contact: Lisa Wang, MD       lisaluwang@gmail.com   
Principal Investigator: Lisa Wang, MD         
United States, Colorado
Exempla Health St Joseph Recruiting
Denver, Colorado, United States, 80218
Contact: Nancy Weber, RN       Nancy.Weber@sclhs.net   
Principal Investigator: Julie Barone, MD         
United States, Connecticut
Greenwich Hospital Recruiting
Greenwich, Connecticut, United States, 06830
Contact: Jennie Melendez, MD       Jennie.Melendez@greenwichhospital.org   
Principal Investigator: Dr Drucker, MD         
Stamford Hospital Recruiting
Stamford, Connecticut, United States, 06902
Contact: Paul Weinstein, MD       pweinstein@stamhealth.org   
Principal Investigator: Paul Weinstein, MD         
United States, Florida
21st Century Oncology Recruiting
Fort Myers, Florida, United States, 33907
Contact: David Rock, MD       drock@rtsx.com   
Contact: Nedra Ore       nore@rtsx.com   
Principal Investigator: David Rock, MD         
The Breast Institute at JFK Medical Center Recruiting
Lake Worth, Florida, United States, 33461
Contact: Jamie Kosik       jamie.kosik@hcahealthcare.com   
Contact: Donalyn LaMarre       Donalyn.Lamarre@HCAhealthcare.com   
Principal Investigator: Beth Ann Lesnikoski, MD         
Baptist Health South Florida Recruiting
Miami, Florida, United States, 33183
Contact: Debbie Eyerdam    786-594-6713    DeborahEy@baptisthealth.net   
Lakes Research Recruiting
Miami Lakes, Florida, United States, 33014
Contact: Yamile Sanchez, ysanchez@lakesresearch.com         
Principal Investigator: Eloy Roman, MD         
Center for Breast Care Recruiting
Savannah, Florida, United States, 31404
Contact: Raymond Rudolph, MD    912-350-5664      
Principal Investigator: Raymond Rudolph, MD         
United States, Georgia
Dekalb Medical Recruiting
Decatur, Georgia, United States
Contact: Ruthie Sweat, RN       ruthie.sweat@dekalbmedical.org   
Principal Investigator: Jayanthi Srinivasiah, MD         
Northeast Georgia Medical Center Recruiting
Gainesville, Georgia, United States, 30501
Contact: Patti Rotunda    770-219-8826    patti.rotunda@nghs.com   
Principal Investigator: Charles Nash, MD         
United States, Illinois
Advanced Breast Care Specialists Recruiting
Bloomingdale, Illinois, United States, 60108
Contact: Jan Charvat       jancharvat1@aol.com   
Principal Investigator: Mary Ahn, MD         
Sub-Investigator: Sara Frederickson, MD         
Sub-Investigator: Gale England, MD         
University Surgical Consultants Recruiting
Elk Grove Village, Illinois, United States, 60007
Contact: Daniela Jevremovic       daniela1587@hotmail.com   
Principal Investigator: Gary Salti, MD         
Advocate Lutheran General Hospital Recruiting
Park Ridge, Illinois, United States, 60068
Contact: Yelizaveta Yanovskaya       Yelizaveta.Yanovskaya@advocatehealth.com   
Principal Investigator: Heidi Memmel, MD         
Hematology/Oncology of The North Shore Recruiting
Skokie, Illinois, United States, 60076
Contact: Marsha Weller       mregwell@yahoo.com   
Principal Investigator: Edward Kaplan, MD         
United States, Indiana
Evansville Surgical Associates Recruiting
Evansville, Indiana, United States, 47710
Contact: David Carlson, MD       brcadoc@aol.com   
Principal Investigator: David Carlson, MD         
Northern Indiana Cancer Research Recruiting
South Bend, Indiana, United States, 46601
Contact: Lori Wiseman    574-647-6821    lbarnaby@memorialsb.org   
Sub-Investigator: Lisa Barnaby, MD         
Principal Investigator: Micheal Rotkis, MD         
United States, Maryland
Signature Breast Care Recruiting
Lanham, Maryland, United States, 20706
Contact: Regina Hampton, MD    301-552-7805    rhampton@signaturebreastcare.com   
Principal Investigator: Regina Hampton, MD         
United States, Michigan
McLaren Health Care Recruiting
Burton, Michigan, United States, 48509
Contact: Elizabeth Bowie, RN       Elizabeth.Bowie@mclaren.org   
Principal Investigator: Dr Klamerus, MD         
Great Lakes Cancer Management Specialists Recruiting
Gross Point Woods, Michigan, United States, 48236
Contact: Carrie Dul, MD       dule@comcast.net   
Principal Investigator: Carrie Dul, MD         
United States, Missouri
St Lukes Cancer Center Recruiting
Kansas City, Missouri, United States, 64111
Contact: Teresa Maag       tmaag@saint-lukes.org   
Principal Investigator: John Shook, MD         
Christian Hospital Recruiting
St Louis, Missouri, United States, 63136
Contact: Alicia Rodgers    314-653-5641    aer6691@bjc.org   
Principal Investigator: Christopher Menendez, MD         
United States, Nebraska
University of Nebraska Recruiting
Omaha, Nebraska, United States, 68198
Contact: Kenneth Cowan, Dr       kcowan@unmc.edu   
Principal Investigator: Kenneth Cowan, MD         
United States, Nevada
Compehensive Cancer Care of Nevada Recruiting
Las Vegas, Nevada, United States
Contact: Laura Devine, RN    702-233-7155    laura.devine@uhsinc.com   
Contact: Linda Cortes, RN       linda.cortes@usoncology.com   
Principal Investigator: Suzanne El Eid, MD         
United States, New Jersey
Virtua Health Recruiting
Willingboro, New Jersey, United States, 08046
Contact: Barbara Brown    609-877-1737    BHBrown@virtua.org   
Principal Investigator: Arnold Baskies, MD         
United States, New York
Ashikari Breast Center Recruiting
Cortlandt Manor, New York, United States, 10567
Contact: Julissa Cruz       jcruz@riversidehealth.org   
Principal Investigator: Pond Keleman, MD         
Sub-Investigator: Ashikari, MD         
United States, Oklahoma
University of Oklahoma Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: Sharon Ross       sharon-ross@ouhsc.edu   
Principal Investigator: William Dooley, MD         
United States, Pennsylvania
Breast Care Specialists Recruiting
Allentown, Pennsylvania, United States, 18104
Contact: Charlotte Bryk       cbyk2@yahoo.com   
Principal Investigator: Mark Gittleman, MD         
ACMH Cancer Center Active, not recruiting
Kittanning, Pennsylvania, United States, 16201
St. Mary Medical Center Recruiting
Langhorne, Pennsylvania, United States, 19047
Contact: Christine Armetta       CArmetta@stmaryhealthcare.org   
Contact: Jennifer Torres    (215) 710-4594    JTorres@stmaryhealthcare.org   
Principal Investigator: Robert Reilly, MD         
Thomas Jefferson University Recruiting
Philadelphia, Pennsylvania, United States, 19107
Contact: Cynthia Perez       Cynthia.Perez@jefferson.edu   
Principal Investigator: Massimo Cristofanilli, MD         
St. Clair Hospital Recruiting
Pittsburgh, Pennsylvania, United States, 15243
Contact: Patsy Thompson       patsy.thompson@stclair.org   
Principal Investigator: Ray Budway, MD         
United States, South Carolina
Cancer Specialists of Charleston Recruiting
Charleston, South Carolina, United States, 29414
Contact: Paul Baron, MD       baronpl@gmail.com   
Contact: Kristy Johnson    843-576-9335      
Principal Investigator: Paul Baron, MD         
The Breast Place Recruiting
Charleston, South Carolina, United States, 29406
Contact: Brandy Pratt-Thomas    843-797-1941    thebreastplacesc@gmail.com   
Principal Investigator: Jennifer Beatty, MD         
Coastal Carolina Breast Center Recruiting
Murrells Inlet, South Carolina, United States, 29576
Contact: Angela Mislowsky, MD    843-651-3308    dr.angelamarie@gmail.com   
Contact: Lorraine Harris    843-651-3308    lharris@gmhsc.com   
Principal Investigator: Angela Mislowsky, MD         
United States, Tennessee
Nashville Breast Center Recruiting
Nashville, Tennessee, United States, 37203
Contact: Kristi Appleton    615-620-5535    Kristie@nashvillebreastcenter.com   
Principal Investigator: Pat Whitworth, MD         
United States, Texas
Texas Tech University Recruiting
Amarillo, Texas, United States
Contact: Dr. Rahman, MD       rakhshanda.rahman@ttuhsc.edu   
Principal Investigator: Dr Rahman, MD         
Sub-Investigator: Misra Subhasis, MD         
Austin Cancer Center Recruiting
Austin, Texas, United States, 78303
Contact: Lauren Youngborg       lyoungborg@austincancercenters.com   
Principal Investigator: Allison Gorrebeck, md         
Dallas Surgical Group Recruiting
Dallas, Texas, United States, 75230
Contact: Tiffany Huber       thuber@dallassurgical.com   
Principal Investigator: Peter Beitsch, MD         
Texas Health Recruiting
Dallas, Texas, United States, 75230
Contact: Walton Taylor, MD       info@allaboutlifebhc.com   
Contact: Suzette Clark       suzetteclark@texashealth.org   
Principal Investigator: Walton Taylor, MD         
McAllen Oncology Recruiting
Edinburg, Texas, United States
Contact: Eugenio Galindo, MD       oncgalindo@aol.com   
Contact: Belinda , RN       belzlinda_1979@yahoo.com   
Principal Investigator: Eugenio Galindo, MD         
East Houston General Surgery Recruiting
Houston, Texas, United States, 77396
Contact: Gabriella Salinas       xxx.Gabriella.Salinas@hcahealthcare.com   
Principal Investigator: Leonidas Miranda, MD         
Kathryn A. Wagner Private Practice Recruiting
San Antonio, Texas, United States, 78205
Contact: Angie Rodriquez       arodriguez1407@sbcglobal.net   
Principal Investigator: Kathryn Wagner, MD         
Radiation Oncology of San Antonio Recruiting
San Antonio, Texas, United States
Contact: Reema Shroff, RN       reema@luminantresearch.com   
Principal Investigator: Marta Dahiya, MD         
United States, Virginia
Virginia Breast Care Recruiting
Charlottesville, Virginia, United States, 22911
Contact: Paulette       pas@vabreastcare.com   
Principal Investigator: Linda Sommers, MD         
Virginia Breast Care Recruiting
Charlottsville, Virginia, United States, 22911
Contact: Paulette    434-984-3483    pas@vabreastcare.com   
Principal Investigator: Linda Sommers, MD         
Rockingham Memorial Hospital Recruiting
Harrisonburg, Virginia, United States, 22801
Contact: Heidi Rafferty, MD       hgorsuch@aol.com   
Principal Investigator: Heidi Rafferty, MD         
Lynchburg Hematology Oncology Clinic Recruiting
Lynchburg, Virginia, United States, 24501
Contact: Donna Washburne, RN       donna.washburn@centrahealth.com   
Principal Investigator: Dwight Oldham, MD         
Sub-Investigator: John MacNeill, MD         
Bon Secours Virginia Breast Center Recruiting
Midlothian, Virginia, United States, 23114
Contact: James Pellicane, MD       jpellicane@aol.com   
Principal Investigator: James Pellicane, MD         
Bon Secours Virginia Breast Center Recruiting
Midlothian, Virginia, United States, 23114
Contact: Sonya Forrest    804-893-8635    Sonya_forrest@bshsi.org   
Principal Investigator: James Pellicane, MD         
United States, Washington
Swedish Cancer Institute Recruiting
Seattle, Washington, United States, 98104
Contact: David Beatty, MD       David.Beatty@swedish.org   
Contact: Desiree Iriarte       Desiree.Iriarte@swedish.org   
Principal Investigator: David Beatty, MD         
Rockwood Clinic Recruiting
Spokane, Washington, United States, 99216
Contact: Marti Wheeler       mwheeler@rockwoodclinic.com   
Principal Investigator: Renu Sinha, MD         
United States, Wisconsin
Bellin Hospital Recruiting
Green Bay, Wisconsin, United States, 54313
Contact: Kathleen Geisen, CCRP       kageis@bellin.org   
Principal Investigator: Patrick Mansky, MD         
Columbia St. Marys Cancer Center Recruiting
Milwaukee, Wisconsin, United States, 53211
Contact: Julie Hugg       jhugg@columbia-stmarys.org   
Principal Investigator: Varsha Sha, MD         
Waukesha Memorial Hospital Recruiting
Waukesha, Wisconsin, United States, 53188
Contact: Kelli Pettit, MD       kpettit@waukeshasurgery.com   
Principal Investigator: Kelli Pettit, MD         
Wheaton Franciscan Healthcare Recruiting
Wauwatosa, Wisconsin, United States, 53226
Contact: Colleen Alex, RN    414-447-2068    Colleen.alex@wfhc.org   
Contact: Vickie Dodge, RN       Vickie.Dodge@wfhc.org   
Principal Investigator: Hanadi Bu-Ali, MD         
Sponsors and Collaborators
Agendia
Investigators
Principal Investigator: Pat Whitworth, MD Nashville Breast Center
Principal Investigator: Stephanie Akbari, MD Reinsch Pierce Family Center for Breast Health
Principal Investigator: Mark Gittleman, MD Breast Care Specialists
Principal Investigator: Peter Beitsch, MD Dallas Surgical Group
  More Information

Additional Information:
No publications provided

Responsible Party: Agendia
ClinicalTrials.gov Identifier: NCT01479101     History of Changes
Other Study ID Numbers: P0339 NBRST Registry
Study First Received: November 18, 2011
Last Updated: March 19, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Agendia:
neo adjuvant, breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases

ClinicalTrials.gov processed this record on July 31, 2014